{"nctId":"NCT03812224","briefTitle":"A Controlled Trial of Erenumab in Migraine Prevention","startDateStruct":{"date":"2019-04-12","type":"ACTUAL"},"conditions":["Migraine"],"count":261,"armGroups":[{"label":"Erenumab","type":"EXPERIMENTAL","interventionNames":["Drug: Erenumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Erenumab","Drug: Placebo"]}],"interventions":[{"name":"Erenumab","otherNames":["AMG 334","Aimovig®"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures.\n* Japanese subjects greater than or equal to 20 to less than or equal to 65 years of age upon entry into screening.\n* History of migraine (with or without aura) for greater than or equal to 12 months before screening according to the International Headache Society Classification ICHD-3 (Headache Classification Committee of the International Headache Society, 2018) based on medical records and/or patient self-report\n* Migraine frequency: Chronic Migraine (CM) or Episodic Migraine (EM) over the 3 months before screening based on the following criteria:\n\n  1. CM is defined as greater than or equal to 15 headache days per month of which greater than or equal to 8 headache days on average across the 3 months meet criteria as migraine days\n  2. EM is defined as less than 15 headache days per month of which at least 4 or more headache days on average across the 3 months meet criteria as migraine days\n\nExclusion Criteria:\n\n* Subjects greater than 50 years of age at migraine onset.\n* History of cluster headache or hemiplegic migraine headache.\n* Unable to differentiate migraine from other headaches.\n* Migraine with continuous pain, in which the subject does not experience any pain-free periods (of any duration) during the 1 month before the screening period.\n* Malignancy, except non-melanoma skin cancers, cervical or breast ductal carcinoma in situ within the last 5 years.\n\nOther exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Mean Monthly Migraine Days (MMD) Over Months 4, 5, and 6 of the Double-blind Treatment Period","description":"A migraine day was any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined either as a migraine with or without aura, lasting for ≥ 4 hours, and meeting at least 1 of the following criteria:\n\n1. ≥ 2 of the following pain features:\n\n   * unilateral\n   * throbbing\n   * moderate to severe\n   * exacerbated with exercise/physical activity\n2. ≥ 1 of the following associated symptoms:\n\n   * nausea\n   * vomiting\n   * photophobia and phonophobia\n\nThe change from baseline in monthly migraine days was calculated as the average number of migraine days per month during the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment period minus the number of migraine days during the 4-week baseline period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.98","spread":null},{"groupId":"OG001","value":"-3.60","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least a 50% Reduction From Baseline in Mean Monthly Migraine Days Over Months 4, 5, and 6 of the DBTP","description":"A migraine day was any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined either as a migraine with or without aura, lasting for ≥ 4 hours, and meeting at least 1 of the following criteria:\n\n1. ≥ 2 of the following pain features:\n\n   * unilateral\n   * throbbing\n   * moderate to severe\n   * exacerbated with exercise/physical activity\n2. ≥ 1 of the following associated symptoms:\n\n   * nausea\n   * vomiting\n   * photophobia and phonophobia","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":null},{"groupId":"OG001","value":"31.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Monthly Acute Migraine-specific Medication Treatment Days Over Months 4, 5, and 6 of the DBTP","description":"An acute migraine-specific medication treatment day is any calendar day during which a participant took a migraine-specific medication (e.g., triptan or ergotamine).\n\nThe change from baseline in monthly acute migraine-specific treatment days was calculated as the average number of migraine-specific treatment days per month during the last 3 months of the 24-week double-blind treatment period minus the number of migraine-specific treatment days during the 4-week baseline period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.10","spread":null},{"groupId":"OG001","value":"-2.57","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":131},"commonTop":["Nasopharyngitis","Constipation","Back pain"]}}}